Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

Buy_SoFi Apr. 24 at 7:52 PM

$1.00+ by EoY Ferring already partnered with $TLTFF and I can only assume the new cohort of test patients are in the process of being treated for NMIBC. More partners will probably knock on the door; MIBC, GBM/Brain, Lung, pancreatic and HSV topical treatment. This has a multi-dollar buyout written all over... $IBRX $GSK $CGON $JNJ

0 · Reply

PenkeInvesting Apr. 24 at 7:52 PM

Fundamental analysis of $JNJ (JOHNSON & JOHNSON) based on financial data and reported results. #JNJ

0 · Reply

Abouelyazeed Apr. 24 at 6:06 PM

$BFRG $INTC $TEM $CRML $JNJ Buy more

0 · Reply

DragonAlgo Apr. 24 at 4:39 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-05-15 | Strike: $230.00 | Type: CALL Option Plan (premium): Entry: $4.22 Stop: $3.04 TP1: $5.49 TP2: $7.18 TP3: $10.14 🔗 https://dragonalgo.com

0 · Reply

MorganHoratio Apr. 24 at 3:53 PM

Here is every stock that is currently worth more than $500B but not currently a member of the $1 Trillion market cap club Micron $MU $569B $AMD $564B $ASML $562B Johnson & Johnson $JNJ $548B The race for the $1T crown is on! The semi-trio $MU, $AMD, and $ASML are leading the charge, with $MU surging toward the $600B mark fueled by massive AI memory demand. While $JNJ remains a solid defensive anchor, the market’s hunger for compute is where the real premium lies. Who joins the Trillion-Dollar Club first? Is it the HBM powerhouse $MU or the lithography king $ASML? Drop your #1 pick in the comments!

0 · Reply

SquirtMaster Apr. 24 at 3:03 PM

$JNJ dip a little more please

0 · Reply

DynamicSupportWorkspace Apr. 24 at 2:45 PM

$JNJ defensive healthcare giant with diversified revenue and stable earnings quality

0 · Reply

Abouelyazeed Apr. 24 at 2:21 PM

$BFRG $INTC $TEM $CRML $JNJ Great opportunity buy more

0 · Reply

ElliottwaveForecast Apr. 24 at 2:12 PM

$JNJ Buyers should enter between 227.8 - 215.8 area to extend daily bull run It is bullish in daily from January-2025 low and expect current pullback to find support in #bluebox area to rally higher. As long as the pullback holds above 215.8, buyers remain in control, https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Elliottwave #JNJ

0 · Reply

billr78 Apr. 24 at 2:02 PM

$JNJ I blame Cramer for this dip.

0 · Reply

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 23, 2026, 6:44 PM EDT - 22 hours ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

Apr 22, 2026, 8:05 AM EDT - 2 days ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 4:00 AM EDT - 2 days ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 21, 2026, 4:22 PM EDT - 3 days ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 7:45 AM EDT - 3 days ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 17, 2026, 10:36 PM EDT - 6 days ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 6 days ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Apr 16, 2026, 10:16 AM EDT - 8 days ago

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

LLY MGTX

Apr 15, 2026, 4:11 PM EDT - 9 days ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 15, 2026, 1:43 PM EDT - 9 days ago

These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results

Apr 15, 2026, 12:37 PM EDT - 9 days ago

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Apr 14, 2026, 10:51 AM EDT - 10 days ago

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:30 AM EDT - 10 days ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

Apr 14, 2026, 6:55 AM EDT - 10 days ago

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:25 AM EDT - 10 days ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:21 AM EDT - 10 days ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:20 AM EDT - 10 days ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 10 days ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 13, 2026, 11:36 AM EDT - 11 days ago

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

JPM DIA TRV

Apr 12, 2026, 2:00 PM EDT - 12 days ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Apr 10, 2026, 8:00 AM EDT - 14 days ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 9, 2026, 7:57 AM EDT - 15 days ago

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Apr 8, 2026, 10:41 AM EDT - 16 days ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 7, 2026, 8:00 AM EDT - 17 days ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Mar 30, 2026, 9:14 AM EDT - 25 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

Mar 28, 2026, 10:00 AM EDT - 27 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 27, 2026, 4:46 PM EDT - 4 weeks ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 6:31 AM EDT - 4 weeks ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 19, 2026, 1:00 PM EDT - 5 weeks ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

Mar 19, 2026, 9:35 AM EDT - 5 weeks ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 18, 2026, 2:23 PM EDT - 5 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

Mar 18, 2026, 1:17 PM EDT - 5 weeks ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 8:31 AM EDT - 5 weeks ago

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 7:49 AM EDT - 5 weeks ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 16, 2026, 11:00 AM EDT - 5 weeks ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 13, 2026, 12:35 PM EDT - 6 weeks ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 12, 2026, 8:00 AM EDT - 6 weeks ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

$Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Mar 5, 2026, 3:55 PM EST - 7 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 7 weeks ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 7 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 8:03 AM EST - 7 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 2, 2026, 4:30 PM EST - 7 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Feb 26, 2026, 2:30 PM EST - 2 months ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 2 months ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 2 months ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 2 months ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 2 months ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 2 months ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:00 PM EST - 2 months ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Buy_SoFi Apr. 24 at 7:52 PM

0 · Reply

PenkeInvesting Apr. 24 at 7:52 PM

Fundamental analysis of $JNJ (JOHNSON & JOHNSON) based on financial data and reported results. #JNJ

0 · Reply

Abouelyazeed Apr. 24 at 6:06 PM

$BFRG $INTC $TEM $CRML $JNJ Buy more

0 · Reply

DragonAlgo Apr. 24 at 4:39 PM

0 · Reply

MorganHoratio Apr. 24 at 3:53 PM

0 · Reply

SquirtMaster Apr. 24 at 3:03 PM

$JNJ dip a little more please

0 · Reply

DynamicSupportWorkspace Apr. 24 at 2:45 PM

$JNJ defensive healthcare giant with diversified revenue and stable earnings quality

0 · Reply

Abouelyazeed Apr. 24 at 2:21 PM

$BFRG $INTC $TEM $CRML $JNJ Great opportunity buy more

0 · Reply

ElliottwaveForecast Apr. 24 at 2:12 PM

0 · Reply

billr78 Apr. 24 at 2:02 PM

$JNJ I blame Cramer for this dip.

0 · Reply

Abouelyazeed Apr. 24 at 11:58 AM

$BFRG $INTC $TEM $CRML $JNJ

0 · Reply

FocusedFlow Apr. 24 at 7:14 AM

$JNJ defensive healthcare giant with diversified revenue and stable earnings quality

0 · Reply

TheChartiste Apr. 24 at 4:05 AM

$JNJ $PFE $MRK $LLY etc. Pharma for the weekend

0 · Reply

TalkMarkets Apr. 24 at 3:24 AM

Our Calculation Of Intrinsic Value: Johnson & Johnson $JNJ https://talkmarkets.com/article/our-calculation-of-intrinsic-value-johnson-johnson-1777001057

0 · Reply

parcha Apr. 23 at 10:52 PM

Cramer says look to these 4 stocks to go with your high-flying tech names $CVS $JNJ $UNH $CAH https://www.cnbc.com/2026/04/23/cramer-says-look-to-these-4-stocks-to-go-with-your-high-flying-tech-names.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

1 · Reply

DragonAlgo Apr. 23 at 10:09 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-24 | Strike: $232.50 | Type: CALL Option Plan (premium): Entry: $0.56 Stop: $0.40 TP1: $0.73 TP2: $0.95 TP3: $1.34 🔗 https://dragonalgo.com

0 · Reply

PittsburghTrader Apr. 23 at 7:46 PM

$JNJ solid

0 · Reply

Pearl_Power Apr. 23 at 7:08 PM

$JNJ oversold bounce

0 · Reply

midcapinvestor3 Apr. 23 at 5:44 PM

$JNJ shit..why pump

0 · Reply

dosaman Apr. 23 at 4:59 PM

$JNJ why is this board so quiet today ?

0 · Reply

Abouelyazeed Apr. 23 at 3:07 PM

$BFRG Before BFRG: failed trials, collapsing stocks, investor panic 📉💊 After BFRG: AI-driven precision, higher success rates, and winning portfolios 📈🧬🚀 $INTC $TEM $CRML $JNJ

0 · Reply

JJBurch Apr. 23 at 1:38 PM

$OSRH Last call friends. BREAKOUT IMMINENT! 1,000% move begins $JNJ $NFLX $TSLA

0 · Reply

Market Cap	544.59B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	21.08
Forward PE	19.55
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	5,697,458
Avg Vol	8,294,308
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	37%
Beta	0.34
Analysts	Strong Sell
Price Target	$254.72